Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Malcy, Columbus & Reabold presentations - Video Webcast Here

EXCLUSIVE: Leo Koot, Exec Chairman, Columbus Energy speaks at London South East's Oil & Gas event
EXCLUSIVE: Stephen Williams, Reabold Resources speaks at London South East's Oil & Gas event


Motif Bio Share Price (MTFB)



Share Price Information for Motif Bio (MTFB)


Share Price: 32.30Bid: 31.90Ask: 32.85Change: 0.00 (0.00%)No Movement on Motif Bio
Spread: 0.95Spread as %: 2.98%Open: 31.75High: 32.90Low: 31.75Yesterday’s Close: 32.30

Motif Bio Plc Ord 1P

Motif Bio is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
32.30
Share Price SpacerBid
31.90
Share Price SpacerAsk
32.85
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
788,381
Share Price SpacerOpen
31.75
Share Price SpacerHigh
32.90
Share Price SpacerLow
31.75
Share Price SpacerClose
32.30
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 296.53m £95.78m 20,000

52 Week High 51.75 52 Week High Date 4-OCT-2017
52 Week Low 25.50 52 Week Low Date 7-SEP-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
37 672,206 116,175 -2.285 -14.14 0.00 0.00


London South East Users info for Motif Bio




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

20-Jul-18
16:35:15
32.30
2,000
Buy* 
31.75
32.30
646.00
UT 
Trade Type:
Uncrossing Trade

20-Jul-18
16:27:38
31.75
2,500
Sell* 
31.90
32.85
793.75
Trade Type:
Ordinary
NonProtected portfolio
Single protected transaction

20-Jul-18
16:25:24
31.4532
100,000
Sell* 
31.90
32.85
31.45k
Trade Type:
Ordinary




View more Motif Bio trades >>

Directors Deals for Motif Bio (MTFB)
Trade DateActionNotifierPriceCurrencyAmountHolding
02-Oct-15Buy
Trade Notifier Information for Motif Bio
John Wilbur Stakes III held the position of Non-Executive Director at Motif Bio at the time of this trade.
 John Wilbur Stakes III
60GBX100,000171850
02-Apr-15Notification of Holding
Trade Notifier Information for Motif Bio
Richard Cecil Eversfield Morgan held the position of Non-Executive Chairman at Motif Bio at the time of this trade.
 Richard Cecil Eversfield Morgan
00190916
02-Apr-15Notification of Holding
Trade Notifier Information for Motif Bio
Charlotta Ginman-Jones held the position of Non-Executive Director at Motif Bio at the time of this trade.
 Charlotta Ginman-Jones
00125000
View more Motif Bio directors dealings >>


Ivyspivey
Posts: 8,296
Opinion:No Opinion
Price:32.30
REVAMP legislation
Sun 12:15
FYI there is proposed legislation going through US to help support the development of new ABs.Ths could be very important here.

https://www.bloomberg.com/view/articles/2018-07-14/beating-the-next-superbug-needs-big-pharma-payoff
Ivyspivey
Posts: 8,296
Opinion:No Opinion
Price:32.30
RE: Nice Summary
Sun 11:53
We have a novel A/B which is safe and effective and a low propensity to develop resistance.
This is important Re product positioningin that Iclaprim will not in the main be used as a drug of last resort to overcome resistant bugs which limits its use but it is a novel AB which can be used in renal impaired patients but also has a reduced risk of developing resistance which is very important for stewRdship.
Interesting Re combinations of treatments which may widen sales potential say if combined with Suplhonamides
snark_hunter
Posts: 72
Opinion:No Opinion
Price:32.30
RE: Nice Summary
Sun 11:34
Ivy, thanks for the link. So on top of all our other positives, we have a novel mode of action that mitigates resistance. Are we in a good place or what?
Ivyspivey
Posts: 8,296
Opinion:No Opinion
Price:32.30
Nice Summary
Sun 10:32
upchuck
Posts: 44
Opinion:No Opinion
Price:32.30
RE: Revenue
Sat 16:33
Yes, their preference has been to find a commercialization partner. They have mentioned they would like to find a partner already generating revenue in the hospital space. This is the million dollar question though, we don't know what the terms will be for a potential partnership. If they are able to find a partner, the purpose is to have them fund commercialization and manufacturing relieving MTFB of the burden of doing it themselves which would result in massive dilution/debt financing and tank the share price. Again, it all goes back to the terms of a potential partnership. This is the real catalyst I believe much more so than an "all clear" NDA submission and even approval. The market wants to be surprised.
View more share chat for Motif Bio (MTFB) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.